Dr. Rachael Turner Pioneers Ovarian Cancer Research with HE4 Biomarker
Dr. Rachael Turner, a dual M.D./Ph.D. specialist in gynecological malignancies, is making strides in ovarian cancer research. As an assistant professor at the University of Rochester Medical Center, she is investigating the role of a biomarker called HE4 in cancer initiation, interaction with the environment, and immunotherapy response. Her ultimate goal is to block HE4 with a targeted drug to improve treatment outcomes.
Turner's journey into medicine was inspired by her family's experiences with cancer. She pursued a dual M.D./Ph.D. program to explore both clinical care and research, ultimately specializing in ovarian cancer. As a Wilmot Cancer Institute fellow, she studied HE4, a biomarker that could help detect and manage the disease.
Currently, Turner is investigating HE4's role in cancer initiation and its impact on immunotherapy. She aims to block the gene product with targeted medication, potentially improving gynecological cancer treatment. Turner's work is crucial, as these cancers can now be managed as chronic illnesses due to advancements in research. Her optimism is fueled by the rapid progress in this field.
Dr. Rachael Turner, driven by her family's experiences and her passion for improving gynecological cancer treatment, is at the forefront of ovarian cancer research. Her work on the HE4 biomarker and its potential blockage with targeted medication could significantly enhance treatment outcomes, transforming these cancers into manageable chronic illnesses.
